{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:02:31Z","timestamp":1792098151942,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,10]]},"abstract":"\n Aims<\/jats:title>\n To investigate the pharmacodynamics, efficacy and safety of empagliflozin as adjunct to insulin in patients with type 1 diabetes.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 75 patients with glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ) concentrations of \u22657.5 to \u226410.5% (\u226558 to \u226491\u2009mmol\/mol) were randomized to receive once\u2010daily empagliflozin 2.5\u2009mg, empagliflozin 10\u2009mg, empagliflozin 25\u2009mg, or placebo as adjunct to insulin for 28\u2009days. Insulin dose was to be kept as stable as possible for 7\u2009days then adjusted, at the investigator's discretion, to achieve optimum glycaemic control. The primary exploratory endpoint was change from baseline in 24\u2010h urinary glucose excretion (\n UGE<\/jats:styled-content>\n ) on day\u20097.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Empagliflozin significantly increased 24\u2010h\n UGE<\/jats:styled-content>\n versus placebo on days\u20097 and 28. On day\u200928, adjusted mean differences with empagliflozin versus placebo in changes from baseline in:\n HbA1c<\/jats:styled-content>\n were \u22120.35 to \u22120.49% (\u22123.8 to \u22125.4\u2009mmol\/mol; all p\u2009<\u20090.05 vs. placebo); total daily insulin dose \u22120.07 to \u22120.09\u2009\n U\/kg<\/jats:styled-content>\n (all p<0.05 vs placebo); and weight were \u22121.5 to \u22121.9\u2009kg (all p\u2009<\u20090.001 vs. placebo). In the placebo, empagliflozin 2.5, 10 and 25\u2009mg groups, respectively, adverse events were reported in 94.7, 89.5, 78.9 and 100.0% of patients, and the rate of symptomatic hypoglycaemic episodes with glucose \u22643.0\u2009mmol\/l not requiring assistance was 1.0, 0.4, 0.5 and 0.8 episodes per 30\u2009days.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In patients with type 1 diabetes, empagliflozin for 28\u2009days as adjunct to insulin increased\n UGE<\/jats:styled-content>\n , improved\n HbA1c<\/jats:styled-content>\n and reduced weight with lower insulin doses compared with placebo and without increasing hypoglycaemia.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12494","type":"journal-article","created":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T01:43:29Z","timestamp":1434505409000},"page":"928-935","source":"Crossref","is-referenced-by-count":141,"title":["Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4\u2010week, randomized, placebo\u2010controlled trial (\n EASE<\/scp>\n \u20101)"],"prefix":"10.1111","volume":"17","author":[{"given":"T. R.","family":"Pieber","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine Medical University of Graz Graz Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Famulla","sequence":"additional","affiliation":[{"name":"Profil Neuss Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eilbracht","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Cescutti","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim France Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Soleymanlou","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Canada Ltd.\/Ltee Burlington Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. E.","family":"Johansen","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Norway K.S Asker Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Woerle","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. C.","family":"Broedl","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kaspers","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH & Co. KG Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0103"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052187"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1589"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.023"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1720"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1203"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1116-6"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01517.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12073"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2338"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2105"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2673"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12188"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70084-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12503"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051013-110046"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.610852"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-013-0411-y"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0822-9"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70120-2"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72227"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005081"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2955"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12494","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.12494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.12494","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:35Z","timestamp":1761870275000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1111\/dom.12494"],"URL":"https:\/\/doi.org\/10.1111\/dom.12494","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]}}}